1. Home
  2. NIM vs VTVT Comparison

NIM vs VTVT Comparison

Compare NIM & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Select Maturities Municipal Fund

NIM

Nuveen Select Maturities Municipal Fund

N/A

Current Price

$8.67

Market Cap

116.6M

Sector

Finance

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

BUY

Current Price

$31.44

Market Cap

129.7M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
NIM
VTVT
Founded
1992
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.6M
129.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NIM
VTVT
Price
$8.67
$31.44
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $54.71
AVG Volume (30 Days)
★ 44.9K
31.9K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 3.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.46
$19.80
52 Week High
$9.94
$44.00

Technical Indicators

Market Signals
Indicator
NIM
VTVT
Relative Strength Index (RSI) 39.64 46.92
Support Level $8.46 $29.48
Resistance Level $9.47 $34.65
Average True Range (ATR) 0.17 1.12
MACD -0.00 0.05
Stochastic Oscillator 41.39 44.54

Price Performance

Historical Comparison
NIM
VTVT

About NIM Nuveen Select Maturities Municipal Fund

Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued. The fund has single operating segment.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: